Engflag

Ceris

Quick links to important sections

Ceris

There is no image.

Method of action: Anticholinergic, Antispasmodic, Urinary Antispasmodic, Urologicals

Treatment option: Bladder Hyperactivity, Cerebrovascular Accident, Enuresis, Incontinence, Parkinsonism, Multiple Sclerosis, Crush Injury, Urinary Frequency

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceris

Property Description
Active ingredient Trospium Chloride
Form Tablet, Extended-release capsule
Pharmacological class Anticholinergic, Muscarinic Antagonist
General purpose Inhibition of muscle spasms in the bladder
Origin Synthetic compound

What is Ceris and What is its Active Ingredient?

Ceris, a recognized prescription-only therapeutic agent, is a synthetic, single-ingredient medicine designed for systemic use. Its active ingredient is the chemical compound Trospium Chloride, which is the core entity of the drug. Trospium Chloride is a quaternary ammonium compound, a key chemical feature that is clinically recognized for limiting the compound's access to the central nervous system, thereby focusing its therapeutic action peripherally. This compound is prepared for oral administration in two main dosage forms: an immediate-release tablet and an extended-release capsule. These solid pharmaceutical preparations consist of Trospium Chloride combined with various pharmaceutical excipients, such as lactose monohydrate, which serve as the necessary base or vehicle.

What Type of Medicine is Ceris (Pharmacological Class)?

Ceris is formally classified as a muscarinic antagonist, which places it within the broader pharmacological group of anticholinergic agents. The action of Ceris is primarily based on its role as a parasympatholytic agent, meaning it blocks specific nerve signals in organs controlled by the parasympathetic nervous system. Trospium Chloride is further described as an antispasmodic agent, a functional characteristic that has been supported by pharmacological studies. The compound's differentiating factor is its quaternary amine structure, which affects its distribution profile compared to tertiary amine anticholinergics.

What is the General Purpose of Trospium Chloride?

The general purpose of Trospium Chloride is to restore a more controlled and relaxed physiological state to the smooth muscle tissue of the bladder. This function is achieved through its primary physiological action: targeted nerve signal blocking that results in a direct muscle calming effect. By reducing the activity of the nerve messengers responsible for activating muscle movement, the compound produces an inhibition of spasms. This fundamental function allows the medicine to generally help relieve the urgency and frequent need for urination, a typical use scenario that enables the detrusor muscle to relax.

Regulatory References

  1. NIH, Trospium Chloride Prescribing Information

What side effects are possible with Ceris?

Possible Side Effects and Safety Information

The official safety profile of Ceris (Trospium Chloride) is documented across several regulatory domains, classifying adverse reactions by frequency and affected body system. The most common effects are generally anticholinergic in nature.

Frequency-Classified Adverse Reactions

Adverse reactions are classified in regulatory documents according to their reported frequency in clinical studies:

  • Very Common (ge 1/10): Dry mouth.
  • Common (ge 1/100 to <1/10): Constipation, Nausea, Dyspepsia, and Headache.
  • Uncommon (ge 1/1,000 to <1/100): Tachycardia and Flatulence.
  • Rare (ge 1/10,000 to <1/1,000): Dizziness, Vision blurred, Urinary retention, and Rash.

Reactions are grouped by system-organ classes, including Gastrointestinal Disorders, Nervous System Disorders, and Cardiac Disorders. The most frequent reactions, such as dry mouth and constipation, are generally reported to occur early in the course of treatment.

Serious Adverse Reactions and Safety Constraints

The regulatory profile identifies rare but serious adverse reactions, documented primarily through post-marketing surveillance, including Angioedema, Anaphylactic reaction, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Rhabdomyolysis.

The medicine is officially contraindicated in patients with conditions such as urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma. Use is not recommended for patients with severe hepatic impairment.

Population-Specific Safety Notes

Specific safety considerations are noted for certain groups. Patients with moderate to severe renal impairment may experience an expected increase in anticholinergic adverse reactions due to increased systemic exposure. Older adults may have a greater risk for Central Nervous System (CNS) effects, including confusion and somnolence.

Overdose and Emergency Response

Ceris overdose is officially documented as an exacerbation of anticholinergic symptoms. These expected manifestations include severe tachycardia (increased heart rate), profound dryness of the mouth, and disorders of micturition (difficulty passing urine). Central nervous system effects such as confusion, agitation, and hallucinations are also documented risks associated with overexposure.

Urgent medical attention must be sought immediately for severe manifestations. Regulatory information specifically documents the risk of angioedema (swelling) of the face, tongue, or larynx, warning that resulting upper airway swelling may be life-threatening. In such cases, the medication must be promptly discontinued, and immediate measures to ensure a patent airway are required.

Management is symptomatic and supportive, as no specific antidote is known. Procedures described in regulatory labeling include gastric lavage and the administration of activated charcoal to reduce systemic absorption. For severe symptoms, treatment with a parasympathomimetic agent may be utilized. ECG monitoring is recommended in the event of overdosage. Population-specific measures include the need for catheterisation if urinary retention occurs and the use of local pilocarpine for glaucoma patients.

Therapeutic Uses of Ceris

What Ceris Treats: Main Uses and Benefits

The primary therapeutic use of Ceris is generally applied across domains where additional symptomatic support is needed to address the disruptive symptoms of Overactive Bladder (OAB).

The medication is commonly used to help manage symptoms related to heightened physiological activity, including urinary urgency, urinary frequency, and urge incontinence. Ceris is also considered relevant for the management of symptoms caused by Neurogenic Detrusor Overactivity (NDO) in specific patient groups, including pediatric patients with NDO.

In clinical scenarios, Ceris supports patients during episodes of heightened discomfort by providing supportive relief when symptoms interfere with routine activities. “The medication may assist with maintaining functional stability and supports improved comfort,” summarizing its role in easing the symptom load. This generally contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Urinary Urgency Ceris is commonly used to help address the sudden, compelling sensation of needing to urinate and may assist with easing the associated symptom burden.

Regulatory References

  1. NIH MedlinePlus overview on Trospium

Eligibility and Restrictions for Use

Ceris (Trospium chloride) is a prescription medication used to treat symptoms of overactive bladder in adults. However, it is not safe or appropriate for every patient.

Contraindications (Who Cannot Use Ceris)

Ceris is strictly contraindicated, and should not be used, in patients with the following conditions due to an increased risk of severe complications:

  • Urinary retention (inability to completely empty the bladder).
  • Gastric retention (delayed emptying of the stomach).
  • Uncontrolled narrow-angle glaucoma (a type of increased eye pressure that is not managed with treatment).
  • Known hypersensitivity or allergic reaction to trospium chloride or any of the drug’s ingredients.

Precautions (Use with Caution)

Certain pre-existing health issues may necessitate a dose adjustment or require careful monitoring by a healthcare provider. These conditions include:

  • Severe renal impairment (kidney disease, generally with a creatinine clearance below 30 mL/min). Dosing is often reduced.
  • Controlled narrow-angle glaucoma (requires careful monitoring).
  • Conditions that may decrease gastrointestinal motility, such as ulcerative colitis, intestinal atony, or myasthenia gravis.

Patients should also avoid alcohol consumption for at least two hours after taking the extended-release capsule due to a potential increase in drowsiness.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The most significant documented interactions for Ceris (budesonide) involve the pharmacokinetic pathway by which the medicine is processed in the body.

Ceris is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. When Ceris is used concurrently with potent inhibitors of this enzyme system, the concentration of Ceris in the bloodstream may increase significantly.

Clinically Relevant Interacting Substances

Interaction Category Examples of Interacting Substances Regulatory Action/Constraint
Potent CYP3A4 Inhibitors Ketoconazole, Itraconazole, Ritonavir, Erythromycin Avoid co-administration. If necessary, close monitoring for increased systemic corticosteroid effects is required, and discontinuation of Ceris or the inhibitor should be considered.
Food/Beverage Grapefruit, Grapefruit Juice Avoid ingestion. Grapefruit and its juice inhibit CYP3A4 activity primarily in the intestinal lining, which approximately doubles the systemic exposure to Ceris.

Additional Considerations

Patients with reduced liver function, such as liver cirrhosis, have demonstrated increased systemic availability of oral budesonide. These patients may require close monitoring for signs of hypercorticism, as the elimination of the medicine is affected.

Official regulatory information notes that concomitant use of oral contraceptives containing ethinyl estradiol does not affect the pharmacokinetics of Ceris, and Ceris does not affect the plasma levels of the contraceptive.

Mechanism of Action

Molecular Mechanism: Interrupting the Acetylcholine Signal

Ceris (Trospium Chloride) functions as a competitive antagonist that directly targets the Muscarinic Acetylcholine Receptors (M-AChR), particularly the M3 subtype, located on the bladder wall. The molecule interrupts the signaling cascade initiated by the neurotransmitter acetylcholine by physically blocking the receptor binding site, thereby preventing the transmission of the contraction signal.

Physiological Consequence: Modulating Detrusor Smooth Muscle Tone

This molecular blockade inhibits involuntary Gq protein signaling, which is required for intracellular calcium release and subsequent muscle fiber shortening. The physiological effect is a direct reduction in the excitability and tone of the detrusor smooth muscle. This mechanism functionally increases bladder wall compliance and modulates detrusor contractile signaling.

Structural Selectivity: Focusing Action on Peripheral Targets

The molecule's quaternary ammonium compound structure imparts a permanent positive charge, a chemical feature that severely restricts its ability to cross the blood-brain barrier (BBB). This results in the localization of its anticholinergic activity primarily at peripheral targets, such as the bladder muscle, and limits central nervous system interaction.

Dosage and Administration Information

How to Use Ceris

Ceris (Trospium Chloride) administration is governed by specific instructions related to its formulation, dosage timing, and frequency. The medicine is available in two forms, both approved for oral use: a 20 mg immediate-release (IR) tablet and a **60 mg extended-release (XR) capsule.

Standard Dosing and Frequency

Formulation Adult Dosing Schedule Maximum Daily Dose
IR Tablet 20 mg twice daily 40 mg
XR Capsule 60 mg once daily 60 mg

The 20 mg IR tablet is typically taken in the morning and evening, while the 60 mg XR capsule is taken once daily, usually in the morning. This regimen establishes the standard daily exposure for the medication.

Administration Requirements and Adjustments

Adherence to timing is critical: both the tablet and the capsule must be taken on an empty stomach, at least one hour before any meal. Both formulations should be swallowed whole with water. The extended-release capsule must never be crushed, chewed, or opened, as this would compromise the timed release of the active ingredient.

Population-Specific Adjustments: For patients with severe renal impairment (CrCl < 30 mL/min), a dose adjustment is mandatory. The 20 mg IR tablet dose is reduced to once daily (at bedtime), and the 60 mg XR capsule is not recommended in this population. Patients should undergo periodic reassessment to determine the continued need for treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ceris (Trospium Chloride)

Evidence for Use in Overactive Bladder (OAB) Symptoms

Research for Overactive Bladder (OAB) symptoms primarily involves short-term, randomized, double-blind, placebo-controlled trials. These studies were conducted across multiple centers and primarily involved adults who experience OAB symptoms like urinary urgency, frequent urination, and urge incontinence. Researchers monitored how symptoms change over time using structured bladder diaries. These diaries provided objective measurements of the average daily number of voids (frequency) and the number of urge incontinence episodes. Secondary outcomes explored included patient-reported outcomes describing perceived discomfort and quality of life.

Studies reported measurements of change in objective bladder diary parameters over the short-term study period. Findings described patterns observed in the studies, where measured daily frequency of urination and urge incontinence episodes were tracked from the baseline measurement. Systematic reviews and meta-analyses, which combine the results of multiple trials, contribute to the broader evidence landscape by helping to contextualize how patients reported their experience during the studied time intervals. This research focuses on the short-term management of episodic symptom patterns.

Evidence for Use in Neurogenic Detrusor Overactivity (NDO)

Research has explored the use of the medicine in specific populations experiencing Neurogenic Detrusor Overactivity (NDO), which is often associated with underlying neurological conditions. This research area includes specialized, often smaller, randomized controlled trials and comparative studies. These studies were evaluated in populations that may include both adults with NDO linked to conditions like Multiple Sclerosis or Parkinson's Disease, as well as pediatric patients with neurogenic bladder dysfunction. The primary focus of these trials was on measuring urodynamic parameters, such as the increase in maximum cystometric capacity and measured changes in bladder compliance, alongside changes in symptomatic outcomes like daily incontinence episodes.

What is Still Uncertain About Ceris Research

A key research limitation is that the follow-up durations for the pivotal efficacy trials were short. This means that long-term outcomes are not fully established regarding the durability of observed changes, and data for very long-term outcomes are still emerging. Furthermore, research focused on direct comparator trials (head-to-head studies against other agents) is often limited in the published evidence landscape. Data for certain groups, such as pregnant women or those with severe comorbidities, remain insufficient, and research is ongoing to expand the understanding of the medicine's patterns of use across different patient contexts.

Frequently Asked Questions (FAQ)

Common questions about Ceris (FAQ)

Q: What happens if I forget to take a dose of Ceris?

A: According to official product instructions, if a dose is missed, regulatory instructions generally indicate taking the dose as soon as it is remembered, ensuring it is at least one hour before the next meal. However, if it is near the time for the next scheduled dose, the regulatory instruction is to skip the missed dose and continue with the regular schedule. Official information strictly advises against taking extra medicine to make up for a missed dose.

Q: Does Ceris make you drowsy or affect your ability to drive?

A: Official safety information for Ceris indicates that the medicine may cause effects such as dizziness, confusion, and somnolence (drowsiness). Due to the potential for these effects, regulatory documents state that patients are advised to refrain from driving or operating heavy machinery until they know how the medicine affects them.

Q: Can I crush or chew the extended-release Ceris capsule?

A: Official prescribing information states that the extended-release (XR) Ceris capsule should be swallowed whole with water. Crushing, chewing, or opening the capsule is not recommended as it would compromise the drug's timed-release mechanism and delivery profile.

Q: What should I do if I think I have taken too much Ceris (overdose)?

A: Official drug information advises contacting a Poison Control Center or seeking emergency medical help immediately if an overdose is suspected. Symptoms of an overdose may include a very fast heartbeat, widened pupils, and increased sensitivity to light.

Q: Is Ceris safe to take during pregnancy or while breastfeeding?

A: Official labeling notes that there are no adequate and well-controlled studies of the drug in pregnant women. Official product information notes that the use of this medicine during pregnancy must be based on a determination of whether the potential benefit justifies the potential risk. Additionally, it is not currently known whether the active ingredient in Ceris is excreted into human milk.

How should Ceris be stored and disposed of?

How to Store and Dispose of Ceris (Trospium Chloride) Tablets

The storage and disposal of Ceris must strictly follow the requirements defined in official regulatory documents to maintain drug stability and safety.

Storage Conditions

  • Temperature: Store the medication at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The temperature may briefly range from 15 C to 30 C.
  • Protection: The product must be protected from excess heat, moisture, and freezing.
  • Container: Keep the medication in the original container and ensure the container is tightly closed.
  • Child Safety: All medication must be kept out of the sight and reach of children.

Disposal Instructions

Do not dispose of Ceris via wastewater or household waste. Unused or expired medication must be handled according to local and national regulations for pharmaceutical waste, which typically requires consulting a pharmacist for guidance on appropriate collection and disposal facilities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagFrance

Equivalent of Ceris found in:

A-Z Index: